logo
The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research

The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research

PROVIDENCE, R.I., Feb. 21, 2025 /CNW/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program. The program is focused on making structural variation detection more accessible to human genomics researchers by providing Nabsys' OhmX platform on consignment to selected labs.
Fifteen (15) RAMP UP grants were awarded in total, with participants currently progressing through various stages of the consignment agreement process. Upon completion, participants will use the OhmX platform to analyze structural variants (SVs) for various applications, including rare disease, cancer, and cell and gene therapy. Some specific applications include the analysis of repeat expansions, orthogonal confirmation of long-read sequencing calls, determining detection sensitivity for rare SVs, and enhanced cytogenetic profiling.
'I look forward to establishing electronic genome mapping as a core service for the Boston Children's Hospital research community. The technology seems promising for high-resolution analysis of structural variants' said Dr. Catherine Brownstein, a RAMP UP recipient at Boston Children's Hospital and Director of the Genomics Core.
The institutions participating in the program include:
Ann & Robert H. Lurie Children's Hospital of Chicago (Dr. Miriam Bornhorst)
Be Biopharma (Dr. Huei-Mei Chen)
Boston Children's Hospital (Dr. Catherine Brownstein)
Brigham and Women's Hospital (Dr. Phillip Michaels)
Drexel University (Dr. Ming Xiao)
Labcorp (Dr. Adam C. Smith)
Seattle Children's Hospital (Dr. Cate Paschal and Dr. Anica Wandler)
Stanford University (Dr. Alexander E. Urban)
Texas A&M University (Dr. Kenneth S. Ramos)
The Jackson Laboratory (Dr. Mark Adams, Dr. Charles Lee, Dr. Feyza Yilmaz)
The Translational and Advanced Medicine Center (Dr. Kevin P. Clancy)
University of Florida (Dr. Eric Wang)
Yale University (Dr. Ryan B. Jensen)
'Collaborations through the OhmX RAMP UP Grant Program represent our commitment to advancing genomic research by empowering the world's leading institutions with cutting-edge technology,' said Craig Kerkove, President & CEO, HTA. 'We are proud to support the groundbreaking work of these researchers, who are at the forefront of understanding and addressing the complexities of genetic diseases and cancer.'
'In awarding OhmX instruments to these prestigious laboratories, we have made a significant step forward in our mission to democratize access to genomic tools,' noted Nabsys CEO, Dr. Barrett Bready. 'This collaboration between Nabsys and HTA exemplifies our shared vision of powering innovation to drive transformative advancements in genomics and healthcare.'
OhmX's electronic nanochannel-based platform allows researchers to conduct targeted and whole-genome structural-variant analysis, leading to a better understanding of disease mechanisms, gene disruption, and complex genomic regions. This improved understanding empowers precision medicine with the potential to create more effective and personalized treatments, while also overcoming the cost and complexity barriers that are typically associated with SV analysis.
About Nabsys 2.0, LLC
The Nabsys 2.0, LLC ('Nabsys') mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis. For more information, visit https://www.nabsys.com.
About Hitachi High-Tech America, Inc.
Hitachi High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide, with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit https://www.hitachi-hightech.com/us/en.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines

Business Wire

time14-07-2025

  • Business Wire

Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today published a whitepaper titled ' Solving the Biosimilar Void in Europe ' that proposes policy recommendations to fully recognize the value of biosimilars and ensure a more sustainable market in Europe. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience. Share Biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered €56 billion in cumulative cost savings across Europe over the past 11 years (2013-2024). 1 However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivize biosimilar competition. With post-marketing challenges, on top of high development costs, many biologics will not face biosimilar competition at the point of loss of exclusivity (LoE) within the next decade. The whitepaper proposes several measures to improve current practices that hinder healthy market competition and timely access to biosimilar medicines: Health Technology Assessment (HTA) needs to be tailored for biosimilars: With its origin in innovative medicine, HTA is a multidisciplinary process that evaluates the medical, social, economic, and ethical implications of health technologies. Some countries often have oversimplified HTA requirements for biosimilars, where reimbursement decisions are solely based on price comparisons and do not take into account biosimilars' additional benefits or where the reference biologic is not reimbursed. In many cases, HTA is relevant, but with limited guidance to properly assess the biosimilar's value. HTA can be more streamlined and tailored to speed up the entry of biosimilars to the market. In some countries, pricing and reimbursement (P&R) policies focus on achieving the lowest possible prices through mechanisms such as price linkage and reference pricing, thereby accelerating price erosion: Out of 28 European countries, 12 countries use external reference pricing methods and 17 countries mandate arbitrary discounts on biosimilar prices at an average of 28% below reference product. 2 Already set at significantly lower levels, biosimilar prices are driven further downward as competition begins, often leading to price erosion that drives players out of the market. Instead of arbitrary price-controls, free pricing will allow price discounts to be achieved naturally through free competition. Tenders often favor a single-winner system and tend to overlook broader qualitative factors such as supply stability and quality assurance: National, regional, and local tenders should support supply diversification and fair competition through multi-winner systems, with greater transparency in communication and more periodic tender reopenings so that late entrants are also given opportunities to participate. Security and stability of supply should be given higher priority in tenders to enhance demand predictability and incentivize manufacturers to secure more robust supply chains. Biosimilar uptake cannot be achieved without the support of physicians and pharmacists who prescribe and dispense these medicines: Incentives extended to healthcare professionals to encourage the prescribing and dispensing of biosimilars vary significantly across European countries. In some countries, prescriber incentives are misaligned, discouraging the use of biosimilar medicines. Incentive programs should be based on shared decision-making between physicians and patients, rather than automatic switching. Gainsharing can be introduced to stimulate biosimilar uptake while preserving competition and autonomy. Education programs for physicians, pharmacists, and patients should be continued to support wider use of biosimilars. 'Biosimilars are not one-size-fits-all, and establishing a sustainable framework for biosimilars requires a nuanced understanding of their heterogeneous applications across clinical settings. It is vital to tailor key solutions that address the unique challenges faced by different product types, prescribing patterns, and patient and disease characteristics. It is also important to consider the future viability of the market when reshaping policies, as the market needs clear signals of long-term sustainability to encourage continued investments in the biosimilar pipeline,' said Adam Levysohn, Vice President and Head of Commercial Strategy Europe, at Samsung Bioepis. 'It is important for healthcare systems to recognize that biosimilars are not merely a cost-saving tool for organizations. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience.' Samsung Bioepis is a biopharmaceutical company that develops and manufactures high-quality biosimilars to accelerate patient access to biologic medicines. As a world leader in biosimilars, Samsung Bioepis has a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Of the 11 biosimilars approved worldwide, eight products are available across Europe. To access the report Solving the Biosimilar Void in Europe, please visit HERE. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.

Nursing students could get debt relief from Boston startup Clasp
Nursing students could get debt relief from Boston startup Clasp

Boston Globe

time09-07-2025

  • Boston Globe

Nursing students could get debt relief from Boston startup Clasp

The company arranges loans for students studying to become nurses, physical therapists, optometrists, and other medical roles. Clasp matches each student borrower with an employer who agrees to hire the student after graduation. The employer also agrees to pay back a portion of the student's loans in return for a commitment of two to three years of work. The result is more workers for participating employers and a reduced debt burden for their workers, according to Clasp chief executive Tess Michaels. Advertisement The company announced on Wednesday that health care providers including Boston Children's Hospital, Memorial Sloan Kettering in New York, and multi-state network Novant Health would participate in the program. The idea for Clasp, which changed its name from Stride Funding last year, germinated while Michaels attended Harvard Business School. Pondering her own tuition costs and asking around, Michaels said she had an 'a-ha' moment. 'What if you could actually tie the cost of education to the outcomes [and] connect the education to the employment,' she said. Advertisement Michaels has raised $30 million of venture capital backing and struck a deal this year with financial lenders to loan $75 million to students. Unlike most other private student loan programs, Clasp's loans don't require a co-signer. Since the company was founded in 2018, more than 10,000 students have gotten loans through its platform, Michaels said. The company makes money from fees it charges participating institutions, but Clasp does not charge students or receive fees on loans. Some prior employment and loan repayment programs foundered because they included penalties if a worker decided to leave a job before their commitment was up, according to George Washington University professor Patricia Pittman, who studies health care workforce issues. Clasp's agreements don't have penalties or allow employers to claw back prior payments. Employers also can't reduce a promised salary or cut benefits. If a worker leaves before the end of their commitment, they face only the loss of future loan repayments. Claw-backs and other harsh repayment provisions are 'potentially exploitative' if workers are financially penalized for leaving early, Pittman said. 'Without the ability to quit, employers have fewer incentives to create healthy, ethical working conditions,' she said. 'The use of these contract breach fees is common with internationally recruited nurses and has led to many abuses as well as below-market wages.' Solving worker shortages will require more worker-friendly terms, Michaels said. 'In order to make a workforce sustainable, you've got to think about how you build trust and loyalty,' she said. North Carolina-based Novant Health started working with Clasp to recruit nurse anesthetists. The goal was to hire nurses for hard-to-fill positions and reduce turnover. 'The workforce of tomorrow depends on how we support students today,' Sebastien Girard, Novant's chief people officer, said in a statement. 'By relieving financial burden upfront, we're building loyalty from day one.' Advertisement The overall shortage of health care workers is getting worse as a growing aging population requires more care and workers from the Baby Boom generation retire. By 2035, the US system faces a shortage of more than 230,000 registered nurses and almost 270,000 licensed practical nurses, according to In Massachusetts, the Michaels wants Clasp to provide a model for the industry to become more creative and generous in recruiting the workers it needs. 'Part of my mission is to reimagine how we think about investing in talent,' she said. 'That just requires a shifting mindset of what is the art of the possible.' Aaron Pressman can be reached at

West Red Lake Gold Provides Madsen Mine Operations Update
West Red Lake Gold Provides Madsen Mine Operations Update

Yahoo

time25-06-2025

  • Yahoo

West Red Lake Gold Provides Madsen Mine Operations Update

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- West Red Lake Gold Mines Ltd. ('West Red Lake Gold' or 'WRLG' or the 'Company') (TSXV: WRLG) (OTCQB: WRLGF) provides an update on ramp-up operations at the Madsen Mine in Red Lake, Ontario. Following the fatal incident at site on the morning of June 16th, the mine and mill were both shut down. The mill restarted after approximately 40 hours. The mine restarted 12 hours after the mill, ramping up to full operations based on personnel availability and within a safety-first structure. 'With the clear exception of the tragic underground incident, ramp-up at the Madsen Mine is progressing well,' said Shane Williams, President and CEO. 'Mill head grades increased in June as we transitioned from the mixed and generally lower-grade material that had been stockpiled during the bulk sample program, which we processed in May, into freshly mined material that should be more representative of average ore grades going forward. The mill has been averaging 650 tonnes per day with 95% gold recovery and has been tested at higher levels several times without issue. 'We look forward to increasing mining rates over the coming months as ramp-up equipment arrives on site and we access additional mining areas, keeping in mind the Company's number one priority is operational safety.' The Madsen Mine started ramp-up operations on May 11th. Initially, mill feed was predominantly sill material that had been stockpiled during the bulk sample program, during which time only stope material was processed. Sill material is mined during level access development and is typically lower grade than stope material. As mining ramps up, the mill head grade has increased. Milled grade has increased from approximately 3 grams per tonne gold ('g/t Au') in the first two days of June to average 6.5 g/t Au from June 12th to 15th as stope material increased in proportion to sill material. Material going through the mill is now generally grading at levels comparable to the Madsen mine bulk sample. Observed grade variability, including days when gold grade jumps notably, is within the expected range for a deposit of this nature. Figure 1. Four-day average milled gold grade from May 11th to June 15th. Stope material started being incorporated in early June. Mined tonnes in 2025 have primarily been drawn from South Austin and McVeigh. Mining will continue in these areas through 2025 and will also incorporate a number of priority stopes from Austin. The mine has consistently produced 650 tonnes of ore per day. The mill was started up at 650 tonnes per day ('tpd') and has run consistently at that rate and proven capable of higher rates (Figure 2). Mill recoveries have been consistent, averaging 95% (Figure 3). Figure 2. Average daily tonnes milled from May 11th to June 3. Average daily gold recovery in the mill from May 11th to June 15th. The tailings and water treatment systems have been operating as planned. The Company has sold 5,250 ounces of gold year to date, at an average price of US$3,330 per oz. Another gold pour is planned for today, Wednesday June 25th. The Company continues to build up its fleet of mining equipment. A R1300G Caterpillar Scoop loader arrived last week. Two additional Epiroc 42-tonne haul trucks have been ordered and are expected on site in August and September. Three Komatsu 4-yard scoops are ordered, with deliveries expected in July. Two Maclean bolters are ordered, for delivery in July and 4. An underground loader being delivered to the Madsen Mine on June 18th. The two underground drills at Madsen have completed a total of 38,393m of definition drilling in 2025, with 19,904m drilled so far in Q2. Recent drilling has been focused on expanding and further defining the high-grade lenses in South Austin previously announced on May 27th, May 13th and February 26th. The charts shown in this news release show data up to June 15th, the day before the incident, so irregularities from the shut down and restart period are not reflected. The technical information presented in this news release has been reviewed and approved by Will Robinson, Vice President of Exploration for West Red Lake Gold and the Qualified Person for exploration at the West Red Lake Project, as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects. ABOUT WEST RED LAKE GOLD MINES West Red Lake Gold Mines Ltd. is a mineral development company that is publicly traded and focused on advancing and developing its flagship Madsen Gold Mine and the associated 47 km2 highly prospective land package in the Red Lake district of Ontario. The highly productive Red Lake Gold District of Northwest Ontario, Canada has yielded over 30 million ounces of gold from high-grade zones and hosts some of the world's richest gold deposits. WRLG also holds the wholly owned Rowan Property in Red Lake, with an expansive property position covering 31 km2 including three past producing gold mines - Rowan, Mount Jamie, and Red BEHALF OF WEST RED LAKE GOLD MINES LTD. 'Shane Williams' Shane Williams President & Chief Executive Officer FOR FURTHER INFORMATION, PLEASE CONTACT: Gwen Preston Vice President Communications Tel: (604) 609-6132 Email: investors@ or visit the Company's website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY STATEMENT AND FORWARD-LOOKING INFORMATION Certain statements contained in this news release may constitute 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information generally can be identified by words such as 'anticipate', 'expect', 'estimate', 'forecast', 'planned', and similar expressions suggesting future outcomes or events. Forward-looking information is based on current expectations of management; however, it is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from the forward-looking information in this news release. Forward-looking information involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other things, market volatility; the state of the financial markets for the Company's securities; fluctuations in commodity prices; and changes in the Company's business plans. Forward-looking information is based on a number of key expectations and assumptions, including without limitation, that the Company will continue with its stated business objectives and its ability to raise additional capital to proceed. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Additional information about risks and uncertainties is contained in the Company's management's discussion and analysis for the year ended December 31, 2024, and the Company's annual information form for the year ended December 31, 2024, copies of which are available on SEDAR+ at The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to the Company. The forward-looking information is made as of the date of this news release and the Company assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law. For more information on the Company, investors should review the Company's continuous disclosure filings that are available on SEDAR+ at Photos accompanying this announcement are available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store